Meeting
2017 ASCO Annual Meeting
The successful phase 3 niraparib ENGOT-OV16/NOVA trial included a substantial number of patients with platinum resistant ovarian cancer (OC).
Authors
Jose Maria Del Campo
Grupo Español de Investigación en Cáncer de Ovario (GEICO) and Vall d'Hebrón University Hospital, Barcelona, Spain
Jose Maria Del Campo , Mansoor Raza Mirza , Jonathan S. Berek , Diane M. Provencher , Guenter Emons , Michel Fabbro , Rosemary Lord , Nicoletta Colombo , Edgar Petru , Robert Michael Wenham , Jorn Herrstedt , Lucy Gilbert , Martin Leonhard Heubner , Antonio Gonzalez Martin , Philippe Follana , Benedict B. Benigno , Anne Dørum , Bj Rimel , Sebastien Hazard , Ursula A. Matulonis
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Ovarian Cancer
Clinical Trial Registration Number
NCT01847274
Citation
J Clin Oncol 35, 2017 (suppl; abstr 5560)
DOI
10.1200/JCO.2017.35.15_suppl.5560
Abstract #
5560
Poster Bd #
382
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Efficacy of niraparib on progression-free survival (PFS) in patients (pts) with recurrent ovarian cancer (OC) with partial response (PR) to the last platinum-based chemotherapy.
First Author: Mansoor Raza Mirza
Poster
2017 ASCO Annual Meeting
Long-term benefit of niraparib treatment of recurrent ovarian cancer (OC).
First Author: Ursula A. Matulonis
Poster
2014 ASCO Annual Meeting
A phase 3 randomized double-blind trial of maintenance with niraparib versus placebo in patients with platinum-sensitive ovarian cancer (ENGOT-OV16/NOVA trial).
First Author: Ursula Matulonis
Poster
2021 ASCO Annual Meeting
Niraparib efficacy and safety in patients with BRCA mutated (BRCAm) ovarian cancer: Results from three phase 3 niraparib trials.
First Author: Antonio Gonzalez Martin